Tislelizumab
Metabolic Response
Children's Cancer Group, Chinamonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Metabolic Response cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Children's Cancer Group, China | Phase 2/3 | B |
Bedamustine Children's Cancer Group, China | Phase 2/3 | B |
Brentuximab Vedotin Children's Cancer Group, China | Phase 2/3 | B |
Inno-206 Children's Cancer Group, China | Phase 2/3 | B |
PREDNISONE TABLETS Children's Cancer Group, China | Phase 2/3 | B |
DACARBAZINE Children's Cancer Group, China | Phase 2/3 | B |
ETOPOSIDE Children's Cancer Group, China | Phase 2/3 | B |
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →